CINGULATE INC

CEO’s large stock‑option buys at Cingulate signal confidence in the FDA‑approved neurodegenerative drug CTx‑1301, a potential market‑shifting breakthrough.

Silva Raul R. exercises $0 stock options at CINGULATE, boosting his stake to 6.5% and signaling insider confidence in the ADHD drug pipeline and future value.

Silva Raul R.’s recent Cingulate Inc. share purchase shows insider confidence amid social‑media buzz, highlighting the company’s growth potential and investor‑relevant risks.

CEO Shane Schaffer’s bulk buy of 6,809 Cingulate shares and warrants signals strong confidence in the biopharma’s upcoming milestones—could spark a rally.